Almac Adds High-Speed Clinical Trial Blistering Equipment at US HQ
News May 15, 2012
Almac has announced the acquisition of the new PharmaWorks TF3 high-speed / large-format blister equipment. The addition addresses a growing industry need for outsourced clinical trial services and follows another recent acquisition, the Bosch GKF 702 over-encapsulation machine.
Both pieces of equipment will be housed in Almac’s North American headquarters in Souderton, PA, reinforcing the company’s global capacity by complementing existing equipment currently in the Craigavon, Northern Ireland global headquarters.
The cGMP-compliant equipment provides added value in Almac’s clinical manufacturing capabilities, strengthening the company’s focus on providing clients with a variety of high quality packaging solutions.
In a broader scope, it lends itself to strengthen Almac’s service portfolio that addresses the clinical packaging, labelling, and distribution needs of global clients.
Features of the TF3 include a 220mm x 290mm form area, colour vision system, automated seal registration, and a programmable punch station.
The machine is equipped with an automated feeder that can accommodate the input of up to 4 different products (tablets or capsules) simultaneously.
Capable of speeds averaging 50 indexes per minute, this machine provides convenient and efficient tool-less changeovers.
Almac evaluated a number of high-quality vendors when looking into the purchase of the new blistering equipment.
The TF3 was chosen based on its flexible and versatile nature and its ability to most suitably fulfil Almac’s need to expand to meet the growing needs of global clients.
“The purchase of the PharmaWorks TF3 machine will allow Almac to fulfil our customer's needs by increasing our blistering capacity,” said Dan Megill, Director of Operations at Almac.
Megill continued, “This machine offers leading functionality and supplies Almac with a highly flexible format to support our various clients and their packaging needs.
PharmaWorks are at the forefront of forming technology and the support we have received from them has been tremendous. We are pleased with this acquisition and expect it to contribute greatly to Almac’s overall productivity while enhancing our core services.”
Ben Brower, PharmaWorks VP, also commented “As our tag line on the TF3 brochure states - “No compromise: efficiency and flexibility across the entire spectrum of blisters”.
I cannot think of a better summary of the TF3. We have included features and technology to solve many of the pharmaceutical industry’s blister production challenges. From our user friendly interface to our laser seal and punch registration features we feel the machine is state-of-the-art.
We are proud to count Almac as a continued customer and partner in providing the highest quality in pharmaceutical blister production.
Almac will be able to offer its customers unparalleled and equal efficiency whether producing HUD type blisters or large BINGO type blisters.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE